Abingworth Offers Home For Big Pharma Pipeline Projects
Closes $582m Clinical Co-Development Fund
The UK-headquartered life sciences investment firm has comfortably exceeded its target of $350m for a fund dedicated to taking on late-stage products, incurring all the clinical and regulatory risk and receiving a pre-negotiated return once the drug is approved.
